Claims
- 1. A sub-unit vaccine for controlling Infectious Pancreatic Necrosis Virus (IPNV) in aquatic species, the sub-unit vaccine comprising IPNV structural proteins VP2 and VP3 assembled as an empty IPNV capsid.
- 2. The vaccine according to claim 1, further comprising a green fluorescent protein.
- 3. The vaccine according to claim 1, wherein the IPNV is a strain selected from the group consisting of West Buxton, Jasper, SP, N1, DRT, Ab, HE, TE, Canada 1, Canada 2, Canada 3 and VR299 strains.
- 4. The vaccine according to claim 3, further comprising an antigen from an aquatic virus other than IPNV selected from the group consisting of: infectious hematopoietic necrosis virus (IHNV), viral hemorrhagic septicemia virus (VHSV), ISAV (Infectious salmon anemia virus), PDV (Pancreas disease virus), Irido virus, and Nodavirus.
- 5. The vaccine according to claim 1, wherein the empty IPNV capsid approximates the size and conformation of a native IPN virus.
- 6. The vaccine according to claim 1, wherein the empty viral capsid has a diameter of about 50 to about 65 nm.
- 7. The vaccine according to claim 1, wherein the VP2 and VP3 structural proteins are encoded by SEQ ID NO: 2.
- 8. The vaccine according to claim 1, further comprising a physiologically acceptable carriers for fish.
- 9. A baculovirus expression vector comprising a polynucleotide sequence encoding for structural proteins VP2-VP4-VP3 of infectious pancreatic necrosis virus and a green fluorescent protein.
- 10. The baculovirus expression vector according to claim 9, wherein the polynucleotide sequence encoding for the infectious pancreatic necrosis virus is SEQ ID NO: 2, and the green fluorescent protein is SEQ ID NO: 1.
- 11. The baculovirus expression vector according to claim 9, wherein the polynucleotide sequence encoding for the green fluorescent protein is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 8, and SEQ ID NO: 9.
- 12. A host cell transfected with the baculovirus expression vector according to claim 9.
- 13. A host cell transfected with the baculovirus expression vector according to claim 10.
- 14. A host cell transfected with the expression vector according to claim 11.
- 15. The host cell according to claim 10, wherein the host cell is an insect cell.
- 16. A method of generating structural proteins of IPNV assembled as an empty viral capsid comprising the steps of:
(a) providing a recombinant baculovirus comprising a polynucleotide encoding IPNV Segment A proteins VP2,-VP4 -VP3, and a reporter protein; (b) infecting insect larvae with the recombinant baculovirus; and (c) maintaining suitable conditions for expression of IPNV Segment A proteins VP2,-VP4-VP3, and the reporter protein to generate structural proteins VP2 and VP3 assembled as an empty IPNV capsid; and (d) recovering the empty IPNV capsid from the larvae.
- 17. The method according to claim 16, wherein the larvae are infected all at the same time and harvested when the reporter protein is expressed.
- 18. The method according to claim 16, wherein suitable conditions comprises:
infecting the larvae with a viral loading of at least 5×107 pfu/mL recombinant baculovirus,; maintaining a temperature of at least about 30° C.; and harvesting of the larvae at least 3-5 days after post infection at a pH of at least about 3.5 to about 4.0.
- 19. A method for reducing and/or preventing infection of IPNV in marine fish by administrating an effective amount of a sub-unit vaccine comprising IPNV structural proteins VP2 and VP3 assembled as an empty IPNV capsid that approximates the size and conformation of a native IPN virus.
- 20. The method according to claim 19, wherein the IPNV is a strain selected from the group consisting of West Buxton, Jasper, SP, N1, DRT, Ab, HE, TE, Canada 1, Canada 2, Canada 3 and VR299 strains.
- 21. The method according to claim 19, wherein the vaccine further comprising an antigen from an aquatic virus other than IPNV selected from the group consisting of: infectious hematopoietic necrosis virus (IHNV), viral hemorrhagic septicemia virus (VHSV), ISAV (Infectious salmon anemia virus), PDV (Pancreas disease virus), Irido virus, and Nodavirus.
- 22. The method according to claim 19, wherein the empty viral capsid resembles the 3D-structure of native IPNV particles and does not include an infectious RNA genome.
- 23. The method according to claim 19, wherein the empty IPNV capsid has a diameter of about 50 to about 65 nm.
- 24. A sub-unit vaccine for controlling Infectious Pancreatic Necrosis Virus (IPNV) in aquatic species, the sub-unit vaccine comprising IPNV structural proteins VP2 and VP3 assembled as an empty IPNV capsid that corresponds to the 3D-structure of a native IPN virus and does not include an infectious RNA genome.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional Patent Application No. 60/311,488 filed on Aug. 10, 2001 by Vikram N. Vikharia entitled “VACCINE FOR INFECTIOUS PANCREATIC NECROSIS VIRUS.”
Provisional Applications (1)
|
Number |
Date |
Country |
|
60311488 |
Aug 2001 |
US |